Method of treating prostatic diseases using active vitamin D ana

Details Method of treating prostatic diseases using active vitamin D ana Method of treating prostatic diseases using active vitamin D ana

1996-12-30

1998-06-09

Criares, Theodore J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

514167, 552653, A61K 3159

Patent

active

057634297

ABSTRACT:
The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.

REFERENCES:
patent: 2383446 (1945-06-01), Calcott et al.
patent: 3697559 (1972-10-01), DeLuca et al.
patent: 3741996 (1973-06-01), DeLuca et al.
patent: 3907843 (1975-09-01), DeLuca et al.
patent: 4195027 (1980-03-01), DeLuca et al.
patent: 4202829 (1980-05-01), DeLuca et al.
patent: 4225596 (1980-09-01), DeLuca et al.
patent: 4234495 (1980-11-01), DeLuca et al.
patent: 4260549 (1981-04-01), DeLuca et al.
patent: 4362710 (1982-12-01), Watanabe
patent: 4508651 (1985-04-01), Baggiolini et al.
patent: 4554106 (1985-11-01), DeLuca et al.
patent: 4555364 (1985-11-01), DeLuca et al.
patent: 4588716 (1986-05-01), DeLuca et al.
patent: 4661294 (1987-04-01), Holick et al.
patent: 4689180 (1987-08-01), Deluca et al.
patent: 4866048 (1989-09-01), Calverley et al.
patent: 5063221 (1991-11-01), Nishii et al.
patent: 5104864 (1992-04-01), DeLuca et al.
patent: 5157135 (1992-10-01), Tsuji et al.
patent: 5403831 (1995-04-01), DeLuca et al.
patent: 5602116 (1997-02-01), Knutson et al.
L.E. Reeve et al., "Biological Activity of 1 .alpha.-hydroxy Vitamin D.sub.2 in the Rat" Arch. Biochem. Biophys. 186, 1, Feb. 1978, pp. 164-167.
Sjoden et al., "Effects of 1 OHD.sub.1 on Bone Tissue" Acta. Endocrinol. (Copenh.) 16, 4, Aug. 1984, pp. 564-568.
N./ Brautbar, "Osteoporosis: Is 1,25-(OH,.sub.2 D.sub.3 of Value in Treatment?" Nephron 44, 1986, pp. 161-166.
Physicians Desk Reference, Edition 43, pp. 1746-1748.
Y. Tanaka et al., Endocrinology, 1973, 92; pp. 417-422.
O.H. Sorenson et al., Clin. Endocrinol., 1977, 7, pp. 169S-175S.
V. Hoikka et al., Acta. Med. Scand., 1980, 207, pp. 221-224.
Brown et al., Lancet, 1984, 1, pp. 1091-1093.
J. Podenphant et al., Acta Med Scand., 1985, 218, pp. 329-333.
Caniggia et al., Calif Tissue Int., 1986, 38, pp. 328-332.
Duda et al., J. Clinic Invest., 1987, 79, pp. 1249-1253.
Sommerfeldt et al., J. Nutr., 1983, 11, pp. 2595-2600.
Zerwebh et al., J. Clin. Endocrinol. Metabol., 1985, 60, pp. 615-617.
Horst et al., Anal. Biochem., 1981, 116, pp. 189-203.
Horst et al., Biochem. J., 1982, 204, pp. 185-189.
Foldes et al., Osteoporosis 1987, C. Christianson et al. (eds.) Osteopress Aps, Copenhagen, pp. 971-973.
Guidelines for the Clinical Evaluation of Drugs Used in the Treatment of Osteoporosis , HEW (FDA) 80-3094, pp. 5-6 (1979).
J.A. Kanis et al., Guidelines for Clinical Trials in Osteoporosis, A Position Paper of the European Foundation for Osteoporosis, Osteoporosis Int., 1991, 1, pp. 182-188.
C. Christiansen et al., "Prevention of Early Postmenopausal Bone Loss: Controlled 2-Year Study in 315 Normal Females," Europ J Clin Invest, 1980, 10, pp. 273-279.
J.M. Pouilles et al., "Prevention of Post-Menopausal Bone Loss with 1 .alpha.-Hydroxy Vitamin D.sub.3, A Three-Year Prospective Study," Clin Rheumatol., 11, 1992, 4, pp. 492-497.
M.F. Holick et al., Proc. Natl. Acad. Sci. USA 68, 803-804 (1971).
G. Jones et al., Biochemistry 14, 1250-1256 (1975).
M.F. Holick et al., Science 180, 190, 191 (1973).
H.Y. Lam et al., Science 486, 1038-1040 (1974).
S.M. Ott, C. H. Chestnut, Annals of Int. Med. 1989, 110:267-274.
J.C. Gallagher et al., Annals of Int. Med. 1990, 113:649-655.
J. Aloia et al., Amer. J. Med. 84:401-08 (1988).
M. Shiraki et al., Endocrinol. Japan 32, 305-315 (1985).
G.F. Jensen et al., Clin. Endocrinol. 16, 515-524 (1982).
C. Christiansen et al., Eur. J. Clin. Invest. 11, 305-309 (1981).
O.H. Sorensen et al., Clin. Endocrinol. 7, 169S-175S (1977).
H. Orimo et al., Bone and Mineral 3, 47-52 (1987).
G. Sjoden et al., J. Nutr. 114, 2043-2046 (1984).
G. Sjoden et al., Proc. Soc. Exp. Biol. Med. 178, 432-436 (1985).
J.C. Gallagher et al., Bone Min. Res.: 1994; 9:607-614.
E. Braunwald et al., Harrison's Principles of Internal Medicine: Part Eleven, "Disorders of Bone and Mineral Metabolism," Chapter 335, McGraw-Hill, New York, 1987, pp. 1860-1865.
W. Grab, Z. Physiol. Chem., 243:63-89 (1936).
F.G. McDonald, J. Biol. Chem., 114:IVX (1936).
A. Windaus et al., Z. Physiol. Chem., 247:185-188 (1937).
DeLuca et al., Arch. Biochem, Biophys., 124:122-128 (1968).
Merck Index, S. Budavari (ed.), 11th ed., Merck & Co., Rahway, N.J. (1989) pp. 1579, #9930.
Barton et al., JCS Perkin I, 1976, 821-826.
Paaren et al., J. Org. Chem., 1980, 45:3253.
S. Weintroub et al., "Dichotomy in the Effects of 1,25 dihydroxy vitamin D.sub.3 and 24,25 dihydroxy vitamin D.sub.3 on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in vitamin D-Deficient Rats," Calcif, Tissue Int. (1987) 40:166-172.
Strugnell et al., Biochem. Pharm. vol. 40:333-341 (1990).
Martin and DeLuca, Am. J. Physiol. 216:1352-1359 (1979).
P.J. Kocienski et al., J.C.S. Perkins I, 1290-1293 (1979).
M. Tsuji et al., Bull. Chem. Soc. Jpn., vol. 63, No. 8, 2233-2238 (1990).
D.R. Crump et al., J.C.S. Perkins Trans. I, 2731-2733 (1973).
Chemical Abstracts, vol. 113, No. 1, 2 Jul. 1990, Columbus, Ohio, US; abstract No. 6683y, Y. Tachibana, `Preparation of 1beta-hydroxyvitamin D.sub.2 and D.sub.3, ` p. 6688; col. 2; *abstract* & JP-A-02 011 563 (Nisshin Flour Miling Co.).
Chemistry Letters, No. 8, Aug. 1985, Tokyo, JP; pp. 1131-1132, H. Nemeto et al., `A stereoselective synthesis of 1 alpha-hydroxy-vitamin D.sub.3 `: *the whole document*.
F. Sato et al., Biochim. Biophys. Acta, vol. 1091 (1991) pp. 188-192.

Affiliated with

Also associated with

Rating

Method of treating prostatic diseases using active vitamin D ana does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating prostatic diseases using active vitamin D ana, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating prostatic diseases using active vitamin D ana will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2199273